Cipher Pharmaceuticals (TSE:CPH) Releases Earnings Results

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) released its quarterly earnings data on Tuesday. The company reported C$0.21 earnings per share for the quarter, FiscalAI reports. The business had revenue of C$17.14 million during the quarter. Cipher Pharmaceuticals had a return on equity of 25.69% and a net margin of 60.82%.

Cipher Pharmaceuticals Price Performance

Shares of Cipher Pharmaceuticals stock traded up C$0.38 on Tuesday, reaching C$17.95. The company’s stock had a trading volume of 18,623 shares, compared to its average volume of 25,815. The company has a quick ratio of 2.67, a current ratio of 1.25 and a debt-to-equity ratio of 0.32. The company has a market capitalization of C$455.77 million, a P/E ratio of 15.08 and a beta of 1.15. The stock has a 50-day moving average price of C$16.66 and a 200-day moving average price of C$16.59. Cipher Pharmaceuticals has a 52-week low of C$12.48 and a 52-week high of C$20.56.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group set a C$17.00 price objective on Cipher Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of C$17.00.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.